Neringa Pratuseviciute, Pawel Lis, Sacha Weber, Nicolas Gruchy, Lionel Arnaud, Dario R. Alessi, Esther Sammler
求助PDF
{"title":"Functional and Structural Characterization of LRRK2 p.V1447L in Parkinson's Disease","authors":"Neringa Pratuseviciute, Pawel Lis, Sacha Weber, Nicolas Gruchy, Lionel Arnaud, Dario R. Alessi, Esther Sammler","doi":"10.1002/mds.30284","DOIUrl":null,"url":null,"abstract":"BackgroundGain‐of‐kinase‐function variants in LRRK2 are a leading cause of monogenic Parkinson's disease (PD).ObjectivesWe tested the functional impact of a novel LRRK2 variant p.V1447L identified in a young‐onset PD patient in vivo in peripheral blood, as well as in a robust cellular assay, alongside other variants in close proximity to V1447.MethodsWe measured LRRK2‐dependent Rab10 phosphorylation in neutrophils and monocytes of a LRRK2 p.V1447L carrier with PD. We performed structural mapping and evaluated the potential impact of other LRRK2 variants at and around LRRK2 V1447.ResultsLRRK2 p.V1447L strongly increases LRRK2 kinase activity. We identified additional variants in the LRRK2 ROC:COR<jats:sub>B</jats:sub> interface with critical impact on kinase activity and demonstrated that different substitutions at the same residue can have opposing effects.ConclusionsWe recommend reclassifying LRRK2 p.V1447L from variant of uncertain significance to likely pathogenic. Our study expands the range of putative loss‐of‐kinase function variants to LRRK2 missense variants. © 2025 The Author(s). <jats:italic>Movement Disorders</jats:italic> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"27 1","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/mds.30284","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
引用
批量引用
LRRK2 p.V1447L在帕金森病中的功能和结构特征
背景:LRRK2中激酶功能的增加变异是单基因帕金森病(PD)的主要原因。目的:我们测试了一种新的LRRK2变体p.V1447L在一名年轻发病的PD患者体内外周血中的功能影响,以及在一个强大的细胞分析中,与其他接近V1447的变体一起。方法在PD患者的LRRK2 p.V1447L携带者的中性粒细胞和单核细胞中检测LRRK2依赖的Rab10磷酸化。我们进行了结构制图,并评估了LRRK2 V1447位点及其周围的其他LRRK2变体的潜在影响。结果slrrk2 p.V1447L显著提高LRRK2激酶活性。我们在LRRK2 ROC:CORB界面中发现了对激酶活性有关键影响的其他变体,并证明了相同残基上的不同取代可能具有相反的效果。结论建议将LRRK2 p.V1447L从意义不确定的变异重新分类为可能致病的变异。我们的研究将假定的激酶功能缺失变异的范围扩大到LRRK2错义变异。©2025作者。Wiley期刊有限责任公司代表国际帕金森和运动障碍学会出版的《运动障碍》。
本文章由计算机程序翻译,如有差异,请以英文原文为准。